Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 | P23786 | 2/20 | 0.45 |
| ▸ | CPT1A | P50416 | 2/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5778766 | 0.82 | KDM4E (0.48) | CPT2CPT1AABHD6ACACBPDE4B | |
| SCHEMBL17607362 | 0.82 | ACACB (0.51) | CPT2CPT1AABHD6ACACBPDE4B | |
| SCHEMBL5773562 | 0.82 | KDM4E (0.43) | CPT2CPT1AABHD6UCHL1ACACB | |
| SCHEMBL5777671 | 0.81 | CHRNB4 (0.51) | CPT2CPT1A | |
| SCHEMBL5777017 | 0.75 | CD44 (0.42) | — | |
| SCHEMBL5775315 | 0.74 | ABHD6 (0.46) | CPT2CPT1AABHD6UCHL1AKR1C3 | |
| SCHEMBL28864977 | 0.72 | ABHD6 (0.49) | CPT2CPT1AABHD6 | |
| SCHEMBL5773186 | 0.71 | HRH3 (0.47) | CPT2CPT1AABHD6ACACBS1PR5 | |
| SCHEMBL22319858 | 0.70 | ABHD6 (0.55) | CPT2CPT1AABHD6ACACBS1PR5 | |
| SCHEMBL17583926 | 0.70 | KDM1A (0.53) | ABHD6UCHL1ACACBPDE4BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | CPT2 1256/4885CPT1A 264/4885ABHD6 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.